[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

Autor: Klimova EA; Yevdokimov Moscow State University of Medicine and Dentistry., Burnevich EZ; Sechenov First Moscow State Medical University (Sechenov University).; City Clinical Hospital №24., Chulanov VP; Sechenov First Moscow State Medical University (Sechenov University).; Central Research Institute of Epidemiology., Gusev DA; Centre for the Prevention and Control of AIDS and Infectious Diseases., Znoyko OO; Yevdokimov Moscow State University of Medicine and Dentistry., Batskikh SN; Central Research Institute of Epidemiology., Kizlo SN; Centre for the Prevention and Control of AIDS and Infectious Diseases., Mamonova NA; Central Research Institute of Epidemiology., Tarkhova EP; R-Pharm., Krasavina EN; R-Pharm., Samsonov MY; R-Pharm., Yushchuk ND; Yevdokimov Moscow State University of Medicine and Dentistry.

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2019 Aug 15; Vol. 91 (8), pp. 67-74. Date of Electronic Publication: 2019 Aug 15.